Perceptive Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Perceptive Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-75,898	Closed	-$12.9M	–	134
2018 Q2	$12.9M	Sell	75,898 -76,000	-50%	-$11.8M	0.34%	55
2018 Q1	$24.8M	Buy	151,898 +13,272	+10%	+$2.17M	0.69%	34
2017 Q4	$20.8M	Hold	138,626	–	–	0.69%	38
2017 Q3	$21.1M	Sell	138,626 -138,726	-50%	-$20.9M	0.81%	30
2017 Q2	$35.7M	Sell	277,352 -16,157	-6%	-$1.94M	1.8%	15
2017 Q1	$32.1M	Buy	293,509 +208,000	+243%	+$18.3M	1.83%	17
2016 Q4	$6.3M	Sell	85,509 -21,491	-20%	-$1.75M	0.45%	52
2016 Q3	$9.33M	Sell	107,000 -23,000	-18%	-$2.17M	0.6%	41
2016 Q2	$11.2M	Sell	130,000 -30,000	-19%	-$2.59M	0.78%	28
2016 Q1	$12.7M	Buy	160,000 +50,000	+45%	+$4.52M	1.12%	22
2015 Q4	$13.8M	Buy	+110,000	New	+$13.3M	1.02%	25
2015 Q1	–	Sell	-110,000	Closed	-$13.1M	–	175
2014 Q4	$13.1M	Sell	110,000 -130,142	-54%	-$14.7M	1.1%	25
2014 Q3	$27M	Sell	240,142 -230,000	-49%	-$21.9M	2.73%	10
2014 Q2	$44.5M	Sell	470,142 -111,586	-19%	-$7.82M	4.37%	4
2014 Q1	$41.1M	Sell	581,728 -230,000	-28%	-$18.2M	4.32%	4
2013 Q4	$60.3M	Buy	811,728 +359,633	+80%	+$25M	7.24%	4
2013 Q3	$34.3M	Buy	452,095 +195,548	+76%	+$15.6M	2.78%	10
2013 Q2	$20.5M	Buy	+256,547	New	+$18.9M	2.07%	12

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Perceptive Advisors's VRTX Position: Q3 2018 in Review

Perceptive Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2018, closing a stake of 75,898 shares — an estimated $12.9M sold.

Perceptive Advisors first reported a position in VRTX in Q2 2013 and held it in 18 quarters. The position peaked at $60.3M in Q4 2013. 697 funds tracked by Wall St. Rank hold VRTX as of Q3 2018.

Perceptive Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Perceptive Advisors sold 75,898 Vertex Pharmaceuticals shares in Q3 2018, an estimated $12.9M.
Perceptive Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 18 quarters.
Perceptive Advisors's Vertex Pharmaceuticals position peaked at $60.3M in Q4 2013.
697 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2018.

Based on Perceptive Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.